(NP (NP-COOD (NP (NP (NN Estrogen) (NN binding) (NNS sites)) (PP (IN in) (NP (JJ peripheral) (NN blood) (NNS monocytes)))) (CC and) (NP (NP (NNS effects)) (PP (IN of) (NP (NN danazol))) (PP (IN on) (NP (NP (PRP$ their) (NNS sites)) (ADVP (FW in) (FW vitro)))))) (. .))
(S (LST (LS 1) (. .)) (NP-SBJ-29 (DT This) (NN study)) (VP (VBD was) (VP (VBN designed) (NP-30 (-NONE- *-29)) (S (NP-SBJ (-NONE- *-30)) (VP (TO to) (VP (VB investigate) (NP-COOD (NP (NP (DT the) (NN presence)) (PP (IN of) (NP (NN estrogen) (NP-COOD (NP (NP (NN type) (CD I)) (PRN (-LRB- -LRB-) (FRAG (NP-COOD (NP (JJ high) (NN affinity)) (, ,) (NP (JJ low) (NN capacity)))) (-RRB- -RRB-))) (CC and) (NP (NP (NN type) (CD II)) (PRN (-LRB- -LRB-) (FRAG (NP-COOD (NP (JJ low) (NN affinity)) (, ,) (NP (JJ high) (NN capacity)))) (-RRB- -RRB-)))) (NN binding) (NNS sites))) (PP (IN in) (NP (JJ human) (JJ peripheral) (NN blood) (NNS monocytes)))) (CC and) (NP (NP (DT the) (NNS effects)) (PP (IN of) (NP (NN danazol))) (PP (IN on) (NP (DT these) (NNS sites)))))))))) (. .))
(S (LST (LS 2) (. .)) (NP-SBJ (NP (DT These) (CD two) (NNS types)) (PP (IN of) (NP (NN estrogen) (NN binding) (NNS sites)))) (VP (VBD existed) (PP (IN in) (NP (JJ human) (JJ peripheral) (NN blood) (NNS monocytes)))) (. .))
(S (LST (LS 3) (. .)) (NP-SBJ (NN Danazol)) (VP-COOD (VP (VBD bound) (PP (TO to) (NP (DT these) (NNS sites))) (PP (IN in) (NP (NP (JJ high) (NN concentration)) (PRN (-LRB- -LRB-) (NP (NP (UCP-COOD (NP (CD 10-LRB--6-RRB-) (NN M)) (, ,) (ADJP (JJ clinical))) (NN serum) (NN concentration)) (PP-TMP (IN during) (NP (NN danazol) (NN therapy)))) (-RRB- -RRB-))))) (CC and) (VP (VBD decreased) (NP (NP (DT the) (NN number)) (PP (IN of) (NP (DT both) (NNS sites)))))) (. .))
(S (LST (LS 4) (. .)) (NP-SBJ (PRP It)) (VP (VBZ is) (VP (VBN suggested) (SBAR (IN that) (S (NP-SBJ (NN danazol)) (VP (VBZ has) (NP (NP (DT an) (JJ anti-estrogenic) (NN action)) (PP (TO to) (NP (DT the) (NNS monocytes)))) (PP (IN through) (NP (NP (DT the) (NP-COOD (NP (NN competition)) (CC and) (NP (NN suppression)))) (PP (IN of) (NP (NN estrogen) (NN binding) (NNS sites))))) (SBAR (IN as) (S (NP-SBJ-31 (-NONE- *)) (VP (VBN seen) (NP (-NONE- *-31)) (PP (IN in) (NP (DT the) (NN estrogen) (NN target) (NN organ))))))))))) (. .))
